GRI Bio Inc
GRI2.390USD
+0.200+9.13%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
42.48KMarket Cap
LossP/E TTM
More Details of GRI Bio Inc Company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
GRI Bio Inc Info
Ticker SymbolGRI
Company nameGRI Bio Inc
IPO dateFeb 10, 2021
CEOHertz (W. Marc)
Number of employees3
Security typeOrdinary Share
Fiscal year-endFeb 10
Address2223 Avenida De La Playa
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone16194001171
Websitehttps://www.gribio.com/
Ticker SymbolGRI
IPO dateFeb 10, 2021
CEOHertz (W. Marc)
Company Executives of GRI Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Albert Agro, Ph.D.
Dr. Albert Agro, Ph.D.
Chief Medical Officer
Chief Medical Officer
4.00
--
Mr. David Charles Baker
Mr. David Charles Baker
Director
Director
--
--
Ms. Leanne M. Kelly
Ms. Leanne M. Kelly
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Dr. W. Marc Hertz, Ph.D.
Dr. W. Marc Hertz, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Szekeres
Mr. David Szekeres
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roelof Rongen
Mr. Roelof Rongen
Independent Director
Independent Director
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Dr. Vipin Kumar Chaturvedi, Ph.D.
Dr. Vipin Kumar Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Albert Agro, Ph.D.
Dr. Albert Agro, Ph.D.
Chief Medical Officer
Chief Medical Officer
4.00
--
Mr. David Charles Baker
Mr. David Charles Baker
Director
Director
--
--
Ms. Leanne M. Kelly
Ms. Leanne M. Kelly
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Dr. W. Marc Hertz, Ph.D.
Dr. W. Marc Hertz, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Szekeres
Mr. David Szekeres
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Jan 7
Updated: Wed, Jan 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
2.96%
Intracoastal Capital, L.L.C.
0.79%
DRW Securities, LLC
0.25%
The Vanguard Group, Inc.
0.04%
Geode Capital Management, L.L.C.
0.03%
Other
95.93%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
2.96%
Intracoastal Capital, L.L.C.
0.79%
DRW Securities, LLC
0.25%
The Vanguard Group, Inc.
0.04%
Geode Capital Management, L.L.C.
0.03%
Other
95.93%
Shareholder Types
Shareholders
Proportion
Corporation
3.75%
Investment Advisor
0.29%
Investment Advisor/Hedge Fund
0.03%
Hedge Fund
0.01%
Other
95.92%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
18
4.80K
0.33%
+3.25K
2025Q3
17
36.64K
1.46%
-11.84K
2025Q2
20
5.55K
0.22%
-27.52K
2025Q1
19
5.33K
0.23%
-27.51K
2024Q4
20
13.78K
9.69%
-11.29K
2024Q3
27
8.71K
9.92%
-9.69K
2024Q2
28
4.88K
16.98%
+3.17K
2024Q1
27
1.68K
35.84%
+996.00
2023Q4
32
776.00
40.40%
+67.00
2023Q3
33
1.00K
63.77%
-329.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
1.20M
11.83%
+1.20M
--
Dec 12, 2025
Intracoastal Capital, L.L.C.
317.98K
3.14%
+317.98K
--
Dec 17, 2025
DRW Securities, LLC
100.61K
0.99%
+100.61K
--
Sep 30, 2025
The Vanguard Group, Inc.
17.00K
0.17%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
12.37K
0.12%
+12.37K
--
Sep 30, 2025
Tower Research Capital LLC
4.02K
0.04%
+190.00
+4.96%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
211.00
0%
--
--
Sep 30, 2025
SBI Securities Co., Ltd.
117.00
0%
--
--
Sep 30, 2025
Agro (Albert)
111.00
0%
--
--
Dec 01, 2025
BofA Global Research (US)
22.00
0%
+3.00
+15.79%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jan 21, 2026
Merger
28→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Jun 14, 2024
Merger
13→1
Date
Ex-dividend Date
Type
Ratio
Jan 21, 2026
Merger
28→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Jan 26, 2024
Merger
7→1
View more
